Image 3 caroussel

Scientific Program

 

Scientific program

 

Wednesday 17th November
13:45-14:00 Opening ceremony
14:00-16:00 Liquid biopsies
16:00-17:00 Poster session (1)
17:00-18:30    
Ions channels & Cancer   Translational research, from biology to the clinic   Health technologies
18:30-19:30 Icebreaker: Drinks & Posters
20:30-23:00 Speaker and moderator dinner, under invitation

 

Thursday 18th November
08:30-10:05 Myeloid cells in cancer
10:05-11:00 Poster session (2)
11:00-12:45 Preneoplasia & Early dissemination
12:45-14:15 Lunch
14:15-16:05    
Cell signaling and therapeutic targets   Genome dynamics and cancer   Patients-partenaire-formateur-co-chercheur : des savoirs expérientiels légitimes ?
16:05-17:00 Break
17:00-18:30 Research in melanoma  
Le patient-partenaire en institution
19:30 Gala dinner, social event

 

Friday 19th November
08:30-10:15    
Poor prognosis cancers: Brain tumors   Extracellular matrix & cancer   Le patient formateur
10:15-11:00 Break
11:00-12:30 Poor prognosis cancers: Pancreatic cancer  
Le patient co--chercheur
12:30-12:45 Poster Awards - Closing ceremony
12:45-14:00 Lunch

 

 

 

Wednesday 17th November

13:45 - 14:00 : Opening ceremony

Scientific director of Cancéropôle Grand Sud-Ouest

 

14:00 - 16:00 : Plenary session

  • Liquid biopsies
    Chairs: Anne-Marie GUE & Fabrice LALLOUE
    • KEYNOTE SPEAKER (virtual): Caroline DIVE, Cancer Biomarker Centre, CRUK Manchester Institute, University of Manchester (United Kingdom) - Liquid biopsies to support better treatment for small cell lung cancer
    • Sandrine DABERNAT, Biotherapy for genetic diseases, inflammation and cancer (Bordeaux) - Extracellular vesicle liquid biopsy: the next generation cancer biomarker ?
    • Camille DANTZER, Bordeaux Research in Translational Oncology - Mutated b-catenin regulates extracellular vesicles machinery in hepatocellular carcinoma
    • KEYNOTE SPEAKER: Valérie TALY, Centre de Recherche des Cordeliers, Inserm U1138, CNRS SNC5096 (Paris) - Tracking circulating tumor DNA for cancer patient follow-up

 

17:00 - 18:30 : Parallel sessions organized by Cancéropôle GSO Axes

  • Ions channels & Cancer / Axis 1 session
    Chair: Bruno CONSTANTIN
    • KEYNOTE SPEAKER: Albrecht SCHWABInstitute of Physiology II, Münster (Germany) - The role of KCa3.1 channels in non-small cell lung cancer
    • Bruno CONSTANTINLaboratoire STIM - CNRS ERL 7003 - EA 7349 (Poitiers) - Calcium signaling in cancer stem cells
    • David MOREAUÉcole des Mines de Saint-Étienne - Manipulation of ionic channels and calcium signaling in glioblastoma with infrared radiation
    • Catherine LECLERCMolecular, cellular and developmental biology Unit, CBI-MCD (Toulouse) - Quiescence status of glioblastoma stem-like cells involves remodelling of Ca2+ signalling and mitochondrial shape

 

  • Translational research, from biology to the clinic : Flash Posters / Axis 3 session
    Chair: Majid KHATIB
    • Alexandra FAUVREMontpellier Cancer Research Institute - Platinum-based chemotherapy induce inflammation via a non-canonical STING pathway dependent on ATM activation
    • Alexia FRANCOISAngiogenesis and Cancer Microenvironment Laboratory (Bordeaux) - Proteolytic protein repression mediates tumor T cells infiltration and anti-tumoral immune response: Drug-repurposing approach
    • Amandine AMALRICInstitute for Functional Genomics (Montpellier) - “Epitranscriptomics”: a promising source of biomarkers for personalized medicine
    • Céline HERVIEU, CAPTuR (Limoges) - Colorectal cancer stem cells respond differently to chemotherapies depending on their original location
    • Elsa FRISTOTStructural Biochemistry Center (Montpellier) - Programming lactic acid bacteria for colorectal cancer therapy
    • Jean DESCARPENTRIEAngiogenesis and Cancer Microenvironment Laboratory (Bordeaux) - Repression of liver colorectal metastasis by the naturally occurring inhibitor of Furin (ppFurin)
    • Johanna MARINESAZELEAD (Montpellier) - Modelling 3D tumour microenvironment in vivo using live imaging technique : a tool to predict cancer fate
    • Kévin BIGOTMontpellier Cancer Research Institute - New Imidazo[1,2-a]quinoxalines compounds for Pancreatic Ductal Adenocarcinoma treatment : mechanism of action and target identification
    • Marine BRUCIAMACCHIEMontpellier Cancer Research Institute - Association of oxaliplatin-based chemotherapy and ATR inhibitor in pancreatic cancer
    • Soha SALLOUMInstitute of Human Genetics (Montpellier) - Characterization of b-catenin translation factories
    • Zeinab TARHINILimoges University - The effect of metformin on the survival of colorectal cancer patients with type 2 diabetes mellitus

 

  • Health technologies / Axis 5 session
    Chair: Anne-Marie GUE
    • EMERGENCE CALLS - Computational biology and models for Cancer
      • Sylvain CUSSAT-BLANC, Institut de Recherche en Informatique de Toulouse - ISiCell : a web-oriented platform to model cellular processes
      • Ovidiu RADULESCU, Laboratory of Pathogen Host Interactions (Montpellier) - Computational Models of Heterogeneity in Melanoma: Designing Therapies and Predicting Outcomes
    • 5 selected talks for "Ma techno en 180 secondes" (flash posters toutes technologies)
      • Malvina MARKU, Cancer Research Center of Toulouse - On the dynamics of TAM formation in Chronic Lymphocytic Leukaemia: a multi-scale approach
      • Chloé BESSIERE, Institute for Regenerative Medicine and Biotherapy (Montpellier) - Towards a novel framework for large scale RNAseq data analysis in human health
      • Alexia BRUNEL, Cancer Research Center of Toulouse - Bioinformatical analysis of tumor cell with stroma crosstalk that impact aggressiveness of pancreatic ductal adenocarcinoma
      • Elisa LAMBERT, XLim (Limoges) - Microfluidic Lab-On-Chip for UHF-Dielectrophoresis Discrimination of Glioblastoma Undifferentiated cells
      • Justine JOURNAUX, Cancer Research Center of Toulouse - Nanotherapy of pancreatic adenocarcinoma by targeted magnetic hyperthermia: efficacy and mechanisms

 

 

Thursday 18th November

08:30 - 10:05 : Plenary session

  • Myeloid cells in cancer 
    Chairs: Mary POUPOT & Nicolas LARMONIER
    • KEYNOTE SPEAKER: Antonio SICA, University of Piemonte Orientale 'A. Avogadro' (Novara) and Humanitas Clinical and Research Center, Milan (Italy) - Therapeutic targeting of myelopoiesis in cancer
    • Frédéric LAGARRIGUEInstitute of Pharmacology and Structural Biology (Toulouse) - Integrin signaling in tumor-associated macrophages
    • Julien FAGETMontpellier Cancer Research Institute - Lessons from the remote alteration of granulopoiesis in NSCLC: what is neutrophil homeostasis telling us on immune checkpoint blockade ?
    • Céline BLAYEInstitut Bergonié and ImmunoConcept Lab (Bordeaux) - The tumor-promoting myeloid landscape in breast cancers

 

11:00 - 12:45 : Plenary session

  • Preneoplasia & early dissemination 
    Chairs: Julie GUILLERMET-GUIBERT & David SANTAMARIA
    • KEYNOTE SPEAKER (virtual): Daniel MUÑOZ-ESPÍN, CRUK Cambridge Centre Early Detection Programme, Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge (United Kingdom) - Impact of cellular senescence in lung precancerous lesions: senotherapeutic opportunities
    • Julie GUILLERMET-GUIBERTCancer Research Center of Toulouse - Role of extrinsic factors in cancer initiation: importance of the stressed niche in pancreatic cancer
    • Zeinab HOMAYED, Institute for Functional Genomics (Montpellier) - Unravelling the role of early dissemination in colorectal cancer
    • Dimitri HAMEL, Digestive Health Research Institute (Toulouse) - Epithelio-stromal relationships in physiology & IBD: osteopontin, a key factor for epithelial regeneration and tumor initiation ?
    • Hamid-Reza REZVANI, Biotherapy for genetic diseases, inflammation and cancer (Bordeaux) - Metabolic and immune features as predictive biomarkers of risk stratification of skin carcinoma

 

14:15 - 16:05 : Parallel sessions organized by Cancéropôle GSO Axes

  • Cell signaling and therapeutic targets / Axis 1 session
    Chair: Violaine MOREAU & Julie PANNEQUIN
    • Damien GREGOIRE, Institute of Molecular Genetics of Montpellier - Ras/MAPK signalling intensity defines subclonal fitness in a mouse model of primary and metastatic hepatocellular carcinoma
    • Lucile BANSARD, Institute for Functionals Genomics (Montpellier) - JMV7048, First-in-class PROTAC degrader of PXR
    • KEYNOTE SPEAKER: David SANTAMARIA, Inserm U1218 Action (Bordeaux) - Novel mechanisms controlling KRAS oncogenic output: impact on tumour fitness and cancer vulnerabilities
    • Coralie CAYRON, Cancer Research Center of Toulouse - PI3K signaling and tumoral metabolism in pancreatic cancer
    • Thomas NAVESCAPTuR (Limoges)Sortilin exhibits tumor suppressor-like activity by limiting EGFR function 
    • Marcin DOMAGALA, Cancer Research Center of Toulouse - Characterization of a novel monoclonal antibody targeting tumor-associated macrophages

 

  • Genome dynamics and cancer / Axis 2 session
    Chair: Gaëlle LEGUBE & Malik LUTZMANN
    • KEYNOTE SPEAKER (virtual): Joanna MORRIS, Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham (United Kingdom) - Back-up pathways that support BRCA1 deficient cells
    • Sébastien BRITTONInstitute of Pharmacology and Structural Biology (Toulouse) - BRCA1 prevents R-loop-associated centromeric instability
    • Israa AL JAMAL, CRIBL (Limoges) - IgH Locus Suicide Recombination (LSR) in Chronic Lymphocytic Leukemia (CLL): Prognosis Indicator ?
    • Yvan CANITROTMolecular, cellular and developmental biology Unit, CBI-MCD (Toulouse) - Control of Homology directed repair of DNA double strand breaks by the KDM8 histone demethylase
    • Francesco CALZAFERRI, Institut des Biomolécules Max Mousseron (Montpellier) - New strategies to target DNA methylation: from the discovery of novel DNMT inhibitors to the identification of novel epigenetic targets
    • Vera PANCALDICancer Research Center of Toulouse - Network approaches to dissect the epigenome-phenotype connection in immune cell

 

  • Patients-partenaire-formateur-co-chercheur : des savoirs expérientiels légitimes ? / session Axe 4
    Modération: 
    • 1 ORATEUR INVITE: Arnaud HALLOY, Université de Nice - Savoirs expérientiels et partenariat patient : une alliance indispensable | Intervention à distance
    • Frédéric BOUHIER, Chargé de mission Société Française de Santé publique - VIH/Sida et Empowerment : « Quels enseignements pour la mobilisation des patients en cancérologie ? »
    • Sabine DUTHEIL, Patiente partenaire Bordeaux - Le cancer du sein, une maladie chronique pas (tout à fait) comme les autres?

 

17:00 - 18:30 : Plenary session and session Axe 4

  • Research in Melanoma
    Chair: 

    • Anne MONTFORTCancer Research Center of Toulouse - Combining TNF inhibitors to anti-PD-1 and anti-CTLA-4 for the treatment of advanced melanoma patients 
    • Xavier ORLIKONERA (Toulouse) - Real time in vivo observation of the human skin microvascularization 
    • Léa DOUSSET, Biotherapy for genetic diseases, inflammation and cancer (Bordeaux) - Vitiligo under PD-1 inhibitors for melanoma patients: what's new and how we can go further ? 
    • KEYNOTE SPEAKER : Daniel PEEPER, The Netherlands Cancer Institute, Amsterdam (The Netherlands) - Rational concepts for tumor & immune cell therapy combinations

 

  • Le patient-partenaire en institution  
    Introduction et modération: Béatrice Jacques
     
    • Sabine DUTHEIL, Patient partenaire (Bordeaux), Delphine GARBAY, Oncologue (Bordeaux) et Hortense FRANCK, Oncoradiothérapeute (Bordeaux) Patiente Partenaire au SEIN d’une équipe d’oncologie : un dispositif innovant
    • Juliane LAMELOT-PELARD, Université de Nantes, Margaux LEBORGNE, Université de Nantes et Bertrand PORRO, Université de Nantes, Angers et Montpellier - Accompagnement des femmes diagnostiquées d'un premier cancer du sein par une patiente-partenaire: Quels bénéfices à moyen et long termes ? Une étude comparative
    • Johanne VASSELLIER, ARS Nouvelle Aquitaine - Une expérimentation innovante : le salariat de patient partenaire en cancérologie

 

 

Friday 19th November

08:30 - 10:15 : Parallel sessions organized by Cancéropôle GSO Axes

  • Poor prognosis Cancers: Brain tumors / Axis 3 session
    Chair: Norbert BAKALARA & Fabrice LALLOUE
    • Thomas DAUBON, Institute for cellular biochemistry and genetics (Bordeaux) - Glioblastoma Metabolic Symbiosis: When Lactate Takes The Lead  
    • Charles DUPIN, Biotherapy of genetic diseases, inflammatory disorders and cancers (Bordeaux) - Glioblastoma, radiotherapy and 5-AminoLevulinic Acid: a dead end ? 
    • Gabriel MARSERES, Immunology from concept and experiments to translation (Bordeaux) - Targeting glioblastoma with in vitro amplified Vd2neg gd T cells: preclinical study 
    • Alexandra GARANCHER, Montpellier Cancer Research Institute - Understanding the immune microenvironment to improve immunotherapy for pediatric brain tumors
    • Jean-Philippe HUGNOT, Institute for Functional Genomics (Montpellier) - Insight on the tumoral cell diversity, their formation and proliferation in IDH1-mutant diffuse low brain gliomas: a key role for Notch1 signaling 

 

  • Extracellular matrix & cancer / Axis 5 session
    Chair: Christine BEZOMBES & Anne-Marie GUE
    • KEYNOTE SPEAKER: Audrey FERRAND, Digestive Health Research Institute (Toulouse) - Extracellular Matrix Mechanical Properties and Regulation of the Intestinal Stem Cells: When Mechanics Control Fate
    • Christine VARON, Bordeaux Research in Translational Oncology - The bacterial genotoxin, cytolethal distending toxin, modulates cell differentiation and elicits epithelial to mesenchymal transition
    • Laure GIBOTMolecular Interactions and Chemical and Photochemical reactivities (Toulouse) - Electric fields as powerful tools to transiently modulate cutaneous extracellular matrix
    • Clément AUGER, CAPTuR (Limoges) - Using nanoparticle tracking analysis (NTA) for appreciation of up and down extracellular vesicle secretion
    • Léa NORMAND, Bordeaux Research in Translational Oncology - Tumor cells-released tracks promote cell migration on type I collagen

 

  • Le patient formateur / session Axe 4
    Introduction et modération: Béatrice Jacques
    • Olivia GROSSLEPS UR 3412, Université Sorbonne Paris Nord - L'expérience de Bobigny | Intervention à distance
    • Marie-France KOLTES, Institut des métiers de la santé et Patrick LARTIGUET, aidant partenaire formateur (Bordeaux) - Du paternalisme médical au partenariat en santé : accompagner le changement auprès des établissements de formation des professionnels de santé
    • Sandra ALLAIRE de la FUENTE, patiente partenaire en oncologie (Bordeaux) - Du témoignage bénévole à la co-construction d’une séquence pédagogique rémunérée
    • Guy KANTOR , ligue contre le cancer en Aquitaine - Lancement d'un dispositif de formation par les patients au sein de la ligue contre le cancer de Gironde Intervention à distance

 

11:00 - 12:30: Plenary session and session Axe 4

  • Poor prognosis Cancers: Pancreatic cancer
    Chair: Marlène DUFRESNE & Véronique GIGOUX  

    • KEYNOTE SPEAKERs: Núria MALATS & Francisco X. REAL, CNIO, Madrid (Spain) - Learning from biology: The challenge of pancreatic cancer prevention
    • Guillaume TOSATO, Montpellier Cancer Research Institute - Discovery of Soluble Pancreatic Cancer Biomarkers Using Innovative Clinical Proteomics and Statistical Learning
    • Yvan MARTINEAU, Cancer Research Center of Toulouse -  Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer
    • Pierre CORDELIER, Cancer Research Center of Toulouse -  Targeting cancer cells with basal-like, mesenchymal phenotype with oncolytic virus to inhibit the growth of pancreatic cancer
    • Corinne BOUSQUET, Cancer Research Center of Toulouse - Towards the identification of Cancer-Associated Fibroblast signaling underlying pancreatic cancer aggressiveness

 

  • Le patient co-chercheur / session Axe 4
    Introduction et modération: Béatrice Jacques
    • Lise MOLIMARD et Nathalie CAPLET, SIRIC Brio - Implication des patients en recherche : retours d'expériences et réflexions sur différentes modalités
    • Julien BIAUDET, Cancéropôle CLARA et Robert Merle, patient partenaire (Lyon) - Construire un appel à projets avec et pour les patients : retour d’expérience du Cancéropôle CLARA
    • Pascal RAGOUET, Centre Emile Durkheim (Bordeaux) - Recherche profane et autothérapie. Quelques pistes sur le concept de recherche translationnelle centrée patient